Total medical devices industry private equity deals in Q1 2020 worth $927.27m were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 54.5% over the previous quarter and a drop of 13.03% when compared with the last four-quarter average, which stood at $1.07bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $870.38m. At the country level, the US topped the list in terms of deal value at $810.3m.
In terms of volumes, North America emerged as the top region for medical devices industry private equity deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of private equity deals activity in Q1 2020 was the US with 16 deals, followed by the UK with three and Canada with two.
In 2020, as of the end of Q1 2020, medical devices private equity deals worth $927.27m were announced globally, marking a decrease of 35.4% year on year.
Medical devices industry private equity deals in Q1 2020: Top deals
The top five medical devices industry private equity deals accounted for 75.5% of the overall value during Q1 2020.
The combined value of the top five medical devices private equity deals stood at $700.2m, against the overall value of $927.27m recorded for the month.
The top five medical devices industry deals of Q1 2020 tracked by GlobalData were:
1) Montagu Private Equity’s $490m private equity deal with RTI Surgical Holdings
2) The $81m private equity deal with Zap Surgical Systems by Chow Tai Fook Enterprises, Hogy Medical, Primavera Capital Group and Shangbay Capital
3) Bain Capital Life Sciences, Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM Capital, Valiance Partners and VI Partners’ $50m private equity deal with JenaValve Technology
4) The $40m private equity deal with Medsphere Systems by TPG Sixth Street Partners
5) Global Emerging Markets’ private equity deal with Avisa Pharma for $39.2m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.